4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024900
CHIEF FINANCIAL OFFICER sold 11,488 shares at an average $27.51 ($316,014)
- CHIEF FINANCIAL OFFICER acquired 11,488 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-04 | Option exercise 10b5-1 | +10,218 | $2.48 | $25,341 | 10,218 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-04 | Sale 10b5-1 | −10,218 | $27.51 | $281,079 | 0 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-07 | Option exercise 10b5-1 | +1,270 | $2.48 | $3,150 | 2,000 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-07 | Sale 10b5-1 | −1,270 | $27.51 | $34,935 | 0 | D |
| Derivatives | |||||||
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-04 | Option exercise · Stock Option (right to buy) 10b5-1 | −10,218 | 182,140 | D | ||
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-07 | Option exercise · Stock Option (right to buy) 10b5-1 | −1,270 | 180,870 | D | ||
| Open-market sales · 11,488 sh · avg $27.51 · $316,014 | |||||||
Loading xslF345X05/form4-10082024_101002.xml…